search
Back to results

Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Primary Purpose

Marginal Zone Lymphoma, Follicular Lymphoma

Status
Recruiting
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
HMPL-689
Sponsored by
Hutchison Medipharma Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Marginal Zone Lymphoma focused on measuring Marginal Zone Lymphoma, Follicular Lymphoma, Phosphatidylinositol 3-kinase inhibitor

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age ≥18 years;
  2. Patients with relapsed/refractory marginal zone lymphoma or follicular lymphoma
  3. Eastern Cooperative Oncology Group (ECOG) Performance Status score 0-2;
  4. At least one measurable lesion by computerised tomography (CT) / magnetic resonance imaging (MRI) (the longest diameter of nodal lesion > 1.5 cm or extranodal lesion > 1 cm);
  5. Expected survival of more than 12 weeks;

Exclusion Criteria:

  1. Having lymphoma with central nervous system (CNS) or cerebral pia mater invasion
  2. Known histologic transformation to aggressive lymphomas such as diffuse large B-cell lymphoma (DLBCL);
  3. Prior use of any phosphatidylinositol 3-kinase (PI3K) inhibitor or Bruton's tyrosine kinase (BTK) inhibitor
  4. Inadequate organ function of liver and kidney
  5. Currently known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)
  6. Having received systemic antitumor therapy or radiotherapy within 4 weeks prior to the first dose of the investigational product
  7. Toxicity of previous antitumor therapy not recovered to CTCAE grade ≤ 1, except alopecia, prior to the first dose of the investigational product
  8. Complicated with uncontrolled systemic infection requiring intravenous antibiotic treatment
  9. Pregnant (positive serum pregnancy test) or lactating women
  10. Any other disease, metabolic abnormality, physical examination abnormality or clinically significant laboratory test abnormality, one disease or state providing a reason to suspect that the subject is not suitable for HMPL-689 at the investigator's discretion, or one condition that will affect interpretation of the study results or bring the subject at high risk.

Sites / Locations

  • The Second Hospital of Anhui Medical University
  • Beijing Chao-yang Hospital ,Capital Medical University
  • Beijing Friendship Hospital, Capital Medical University
  • Beijing Cancer Hospital
  • Peking University Third Hospital
  • Chongqing University Cancer Hospital
  • Fujian Cancer Hospital
  • The First Affiliated Hospital of Xiamen University
  • Sun Yat-sen University Cancer CenterRecruiting
  • Nanfang Hospital, Southern Medical University
  • Cancer Hospital of Shantou University Medical College
  • Guangxi Medical University Affiliated Tumor Hospital
  • Hainan General Hospital
  • Puyang Oilfield General Hospital
  • Henan Cancer Hospital
  • Henan Provincial People's Hospital
  • The First Affiliated Hospital of Zhengzhou University
  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
  • People's Hospital of Wuhan University
  • HuNan Cancer Hospital
  • The Central Hospital of YongZhou
  • The First People's Hospital of Nantong
  • The First Affiliated Hospital of Nanchang University
  • The First Hospital of Jilin University
  • The affiliated hospital of Qingdao University
  • Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine
  • Fudan University Shanghai Cancer CenterRecruiting
  • Shanxi Bethune Hospital
  • West China Hospital Sichuan University
  • Affiliated Hospital of North Sichuan Medical College
  • Tianjin Medical University Cancer Institute and Hospital
  • Cancer Hospital Affiliated to Xinjiang Medical University
  • First Affiliated Hospital of Kunming Medical University
  • The First Affiliated Hospital, Zhejiang University School of Medicine
  • Zhejiang Cancer Hospital
  • The First Affiliated Hospital of Wenzhou Medical University

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Relapsed/Refractory MZL and FL

Arm Description

Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Outcomes

Primary Outcome Measures

Overall response rate (ORR)
Defined as the proportion of patients with CR or PR

Secondary Outcome Measures

Complete response (CR) rate
Defined as the proportion of patients with CR.
Progression-free survival (PFS)
Defined as the time from the first dose of HMPL-689 to occurrence of PD or death, whichever comes first.
Time to response (TTR)
Defined as the time from the first dose of HMPL-689 to the first objective response.
Duration of response (DoR)
Defined as the time from the initial objective response to disease recurrence, progression or death.

Full Information

First Posted
April 13, 2021
Last Updated
June 7, 2021
Sponsor
Hutchison Medipharma Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT04849351
Brief Title
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Official Title
A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients With Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Recruiting
Study Start Date
April 14, 2021 (Actual)
Primary Completion Date
April 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hutchison Medipharma Limited

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL)
Detailed Description
This is a multi-center, single-arm, open-label clinical study to evaluate the oral therapy with HMPL-689 in patients with relapsed / refractory MZL and FL. Relapse / refractory is defined as such a situation when a patient has not achieved response (CR or PR) after the latest line of systemic treatment, or has disease progress (PD) or relapse after achieving response. Two (2) cohorts of patients will be enrolled in this study: Cohort 1: approximately 81 patients with histologically confirmed MZL Cohort 2: approximately 104 patients with histologically confirmed FL (pathological grade 1-3a) All patients are to receive monotherapy of HMPL-689 30 mg once a day (QD) continuously in 28-day treatment cycles until PD / recurrence, patient death, intolerable toxicity, initiation of other antitumor therapy, the patient unable to further benefit from the study treatment as judged by the investigators, the patient or his/her legal representative's request to withdraw from the clinical study treatment, the patient lost to follow-up or end of the study, whichever comes first.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Marginal Zone Lymphoma, Follicular Lymphoma
Keywords
Marginal Zone Lymphoma, Follicular Lymphoma, Phosphatidylinositol 3-kinase inhibitor

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
185 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Relapsed/Refractory MZL and FL
Arm Type
Experimental
Arm Description
Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Intervention Type
Drug
Intervention Name(s)
HMPL-689
Other Intervention Name(s)
Phosphatidylinositol 3-kinase-δ inhibitor
Intervention Description
All patients are to receive monotherapy of HMPL-689 30 mg QD continuously in 28-day treatment cycles.
Primary Outcome Measure Information:
Title
Overall response rate (ORR)
Description
Defined as the proportion of patients with CR or PR
Time Frame
Baseline up to the last patient has completed 12 months after treatment.
Secondary Outcome Measure Information:
Title
Complete response (CR) rate
Description
Defined as the proportion of patients with CR.
Time Frame
Baseline up to the last patient has completed 12 months after treatment.
Title
Progression-free survival (PFS)
Description
Defined as the time from the first dose of HMPL-689 to occurrence of PD or death, whichever comes first.
Time Frame
Baseline up to the last patient has completed 12 months after treatment.
Title
Time to response (TTR)
Description
Defined as the time from the first dose of HMPL-689 to the first objective response.
Time Frame
Baseline up to the last patient has completed 12 months after treatment.
Title
Duration of response (DoR)
Description
Defined as the time from the initial objective response to disease recurrence, progression or death.
Time Frame
Baseline up to the last patient has completed 12 months after treatment.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥18 years; Patients with relapsed/refractory marginal zone lymphoma or follicular lymphoma Eastern Cooperative Oncology Group (ECOG) Performance Status score 0-2; At least one measurable lesion by computerised tomography (CT) / magnetic resonance imaging (MRI) (the longest diameter of nodal lesion > 1.5 cm or extranodal lesion > 1 cm); Expected survival of more than 12 weeks; Exclusion Criteria: Having lymphoma with central nervous system (CNS) or cerebral pia mater invasion Known histologic transformation to aggressive lymphomas such as diffuse large B-cell lymphoma (DLBCL); Prior use of any phosphatidylinositol 3-kinase (PI3K) inhibitor or Bruton's tyrosine kinase (BTK) inhibitor Inadequate organ function of liver and kidney Currently known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) Having received systemic antitumor therapy or radiotherapy within 4 weeks prior to the first dose of the investigational product Toxicity of previous antitumor therapy not recovered to CTCAE grade ≤ 1, except alopecia, prior to the first dose of the investigational product Complicated with uncontrolled systemic infection requiring intravenous antibiotic treatment Pregnant (positive serum pregnancy test) or lactating women Any other disease, metabolic abnormality, physical examination abnormality or clinically significant laboratory test abnormality, one disease or state providing a reason to suspect that the subject is not suitable for HMPL-689 at the investigator's discretion, or one condition that will affect interpretation of the study results or bring the subject at high risk.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xianlin Duan
Phone
021-20678852
Email
xianlind@hmplglobal.com
First Name & Middle Initial & Last Name or Official Title & Degree
Meiping Kong
Phone
86 21 2067 3233
Email
meipingk@hmplglobal.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
junning Cao, Ph.D
Organizational Affiliation
Fudan University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Zhiming Li, post-doc
Organizational Affiliation
Sun Yat-sen University
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Second Hospital of Anhui Medical University
City
Hefei
State/Province
Anhui
ZIP/Postal Code
230601
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
zhimin Zhai, Ph.D
Email
Zzzm889@163.com
First Name & Middle Initial & Last Name & Degree
zhimin Zhai, Ph.D
Facility Name
Beijing Chao-yang Hospital ,Capital Medical University
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100020
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
aijun Liu, Ph.D
Email
laj0628@163.com
First Name & Middle Initial & Last Name & Degree
aijun Liu, Ph.D
Facility Name
Beijing Friendship Hospital, Capital Medical University
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100050
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
zhao Wang, Ph.D
Email
zhaowww263@yahoo.com
First Name & Middle Initial & Last Name & Degree
zhao Wang, Ph.D
Facility Name
Beijing Cancer Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100142
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
yuqing Song, post-doc
Email
SongYQ_VIP@163.com
First Name & Middle Initial & Last Name & Degree
yuqing Song, post-doc
Facility Name
Peking University Third Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100191
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
hongmei Jin, Ph.D
Email
Jinghm@yahoo.com
First Name & Middle Initial & Last Name & Degree
hongmei Jin, Ph.D
Facility Name
Chongqing University Cancer Hospital
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
400030
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
yao Liu, Ph.D
Email
648283926@qq.com
First Name & Middle Initial & Last Name & Degree
yao Liu, Ph.D
Facility Name
Fujian Cancer Hospital
City
Fuzhou
State/Province
Fujian
ZIP/Postal Code
350014
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
yu Yang, Bachelor
Email
yangyu90l@l63.com
First Name & Middle Initial & Last Name & Degree
yu Yang, Bachelor
Facility Name
The First Affiliated Hospital of Xiamen University
City
Xiamen
State/Province
Fujian
ZIP/Postal Code
361001
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
bing Xu, Ph.D
Email
xubingzhangjian@126.com
First Name & Middle Initial & Last Name & Degree
bing Xu, Ph.D
Facility Name
Sun Yat-sen University Cancer Center
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510060
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
zhiming Li, Post-doc
Email
lzmsysu@163.com
First Name & Middle Initial & Last Name & Degree
zhiming Li, Post-doc
Facility Name
Nanfang Hospital, Southern Medical University
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510515
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ru Feng, Master
Email
ruth1626@126.com
First Name & Middle Initial & Last Name & Degree
ru Feng, Master
Facility Name
Cancer Hospital of Shantou University Medical College
City
Shantou
State/Province
Guangdong
ZIP/Postal Code
515031
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
yingcheng Lin, Master
First Name & Middle Initial & Last Name & Degree
yingcheng Lin, Master
Facility Name
Guangxi Medical University Affiliated Tumor Hospital
City
Nanning
State/Province
Guangxi
ZIP/Postal Code
530021
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
hong Cen, Ph.D
Email
cen_hong@163.com
First Name & Middle Initial & Last Name & Degree
hong Cen, Ph.D
Facility Name
Hainan General Hospital
City
Haikou
State/Province
Hainan
ZIP/Postal Code
570311
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
lier Lin, Master
Email
Linlier268@163.com
First Name & Middle Initial & Last Name & Degree
lier Lin, Master
Facility Name
Puyang Oilfield General Hospital
City
Puyang
State/Province
Henan
ZIP/Postal Code
410900
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
xuejun Guo, Master
First Name & Middle Initial & Last Name & Degree
xuejun Guo, Master
Facility Name
Henan Cancer Hospital
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450003
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
keshu Zhou, Ph.D
Email
drzhouks77@163.com
First Name & Middle Initial & Last Name & Degree
keshu Zhou, Ph.D
Facility Name
Henan Provincial People's Hospital
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450003
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
zunmin Zhu, Ph.D
Email
huzm1964@163.com
First Name & Middle Initial & Last Name & Degree
zunmin Zhu, Ph.D
Facility Name
The First Affiliated Hospital of Zhengzhou University
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450052
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ling Li, Ph.D
Email
LingL510@126.com
First Name & Middle Initial & Last Name & Degree
Ling li, Ph.D
Facility Name
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430000
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
liling Zhang, Ph.D
Email
lily1228@sina.com
First Name & Middle Initial & Last Name & Degree
liling Zhang, Ph.D
Facility Name
People's Hospital of Wuhan University
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430061
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
weiping Tao, Master
Email
taowpwp@sina.com
First Name & Middle Initial & Last Name & Degree
weiping Tao, Master
Facility Name
HuNan Cancer Hospital
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410013
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
hui Zhou, Ph.D
Email
zhouhui9403@126.com
First Name & Middle Initial & Last Name & Degree
hui Zhou, Ph.D
Facility Name
The Central Hospital of YongZhou
City
Yongzhou
State/Province
Hunan
ZIP/Postal Code
425006
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
sijuan Ding, Master
Email
874663807@qq.com
First Name & Middle Initial & Last Name & Degree
sijuan Ding, Master
Facility Name
The First People's Hospital of Nantong
City
Nantong
State/Province
Jiangsu
ZIP/Postal Code
226001
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
meihua Ji, Master
Email
13813602152@163.com
First Name & Middle Initial & Last Name & Degree
meihua Ji, Master
Facility Name
The First Affiliated Hospital of Nanchang University
City
Nanchang
State/Province
Jiangxi
ZIP/Postal Code
330006
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
fei Li, Master
Email
yx021021@sina.com
First Name & Middle Initial & Last Name & Degree
fei Li, Master
Facility Name
The First Hospital of Jilin University
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130000
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
sujun Gao, Ph.D
Email
sujung1963@163.com
First Name & Middle Initial & Last Name & Degree
sujun Gao, Ph.D
Facility Name
The affiliated hospital of Qingdao University
City
Qingdao
State/Province
Shandong
ZIP/Postal Code
266000
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
hongwei Xue, Ph.D
Email
hwx326@sina.com
First Name & Middle Initial & Last Name & Degree
hongwei xue, Ph.D
Facility Name
Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200092
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
wenhao Zhang, Ph.D
Email
ZWHL98@FOXMAIL.COM
First Name & Middle Initial & Last Name & Degree
wenhao Zhang, Ph.D
Facility Name
Fudan University Shanghai Cancer Center
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200433
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
junning Cao, Ph.D
Email
caojunning@126.com
First Name & Middle Initial & Last Name & Degree
junning Cao, Ph.D
Facility Name
Shanxi Bethune Hospital
City
Taiyuan
State/Province
Shanxi
ZIP/Postal Code
30002
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
qiaohua Zhang, Bachelor
Email
4792158@qq.com
First Name & Middle Initial & Last Name & Degree
qiaohua zhang, Bachelor
Facility Name
West China Hospital Sichuan University
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610041
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
liqun Zou, Ph.D
Email
zliqun@hotmail.com
First Name & Middle Initial & Last Name & Degree
liqun Zou, Ph.D
Facility Name
Affiliated Hospital of North Sichuan Medical College
City
Nanchong
State/Province
Sichuan
ZIP/Postal Code
637000
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
jin Wei, Master
Email
1497058875@qq.com
First Name & Middle Initial & Last Name & Degree
jin Wei, Master
Facility Name
Tianjin Medical University Cancer Institute and Hospital
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300060
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
shiyong Zhou, Ph.D
Email
zsy1003@medmail.com.cn
First Name & Middle Initial & Last Name & Degree
shiyong Zhou, Ph.D
Facility Name
Cancer Hospital Affiliated to Xinjiang Medical University
City
Ürümqi
State/Province
Xinjiang
ZIP/Postal Code
830000
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
shune Yang, Master
Email
yangshune@yeah.net
First Name & Middle Initial & Last Name & Degree
shune Yang, Master
Facility Name
First Affiliated Hospital of Kunming Medical University
City
Kunming
State/Province
Yunnan
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
jin Liang, Master
Email
liangjinkm@163.com
First Name & Middle Initial & Last Name & Degree
jin Liang, Master
Facility Name
The First Affiliated Hospital, Zhejiang University School of Medicine
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310003
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
zhen Cai, Ph.D
Email
caizhen1@sina.com
First Name & Middle Initial & Last Name & Degree
zhen Cai, Ph.D
Facility Name
Zhejiang Cancer Hospital
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310022
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
haiyan Yang, Ph.D
Email
haiyanyang1125@163.com
First Name & Middle Initial & Last Name & Degree
haiyan Yang, Ph.D
Facility Name
The First Affiliated Hospital of Wenzhou Medical University
City
Wenzhou
State/Province
Zhejiang
ZIP/Postal Code
325000
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
yi Chen, Bachelor
Email
Chenyi9527@163.com
First Name & Middle Initial & Last Name & Degree
yi Chen, Bachelor

12. IPD Sharing Statement

Learn more about this trial

Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

We'll reach out to this number within 24 hrs